Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cardiac amyloidosis: when to suspect and how to confirm.
J Cardiovasc Med (Hagerstown)
February 2025
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste.
Diagnosing cardiac amyloidosis (CA) is challenging because of its phenotypic heterogeneity, multiorgan involvement requiring interaction among experts in different specialties and subspecialties, lack of a single noninvasive diagnostic tool, and still limited awareness in the medical community. Missing or delaying the diagnosis of CA may profoundly impact on patients' outcomes, as potentially life-saving treatments may be omitted or delayed. The suspicion of CA should arise when "red flags" for this condition are present, together with increased left ventricular wall thickness.
View Article and Find Full Text PDFRecovery of Myocardial Functions After Kidney Transplantation in Patients with Heart Failure Due to Uremic Cardiomyopathy.
Turk Kardiyol Dern Ars
January 2025
Department of Cardiology, Istanbul Basaksehir Cam and Sakura City Hospital, Basaksehir, Istanbul, Türkiye.
Objective: Although left ventricular hypertrophy frequently accompanies end-stage renal disease, heart failure (HF) with reduced ejection fraction (EF) is also observed in a subset of patients. In those patients kidney transplantation (KT) is generally avoided due to an increased risk of mortality in addition to the risks associated with HF. This prospective study was designed to follow patients with HF who were being prepared for KT.
View Article and Find Full Text PDFCardiotoxicity and peri-operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review.
Anaesthesia
February 2025
Department of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.
Introduction: Immunotherapy has transformed cancer treatment, particularly with immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Despite their efficacy, these therapies can induce cardiotoxicity, presenting significant clinical challenges. Immune checkpoint inhibitors can cause myocarditis; pericarditis; arrhythmias; and myocardial infarction through immune-mediated inflammation.
View Article and Find Full Text PDFA case report: Endobronchial ultrasound guided biopsy of radiographically normal size thoracic lymph nodes supporting diagnosis of cardiac sarcoidosis.
Respir Med Case Rep
November 2024
Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- Sarcoidosis is a rare chronic disease with an unclear cause, making cardiac sarcoidosis (CS) diagnosis particularly challenging.
- Current guidelines for diagnosing CS lack clinical validation, and while endomyocardial biopsy is specific, it is not very sensitive and has significant risks.
- A case study of a 63-year-old man diagnosed with CS through endobronchial ultrasound transbronchial needle aspiration (EBUS TBNA) of normal lymph nodes suggests that EBUS TBNA could be a viable option for diagnosing CS in cases without clear pulmonary sarcoidosis evidence.
A 68-Year-Old Colombian Man Presenting with Heart Failure and a Diagnosis of Cardiac Transthyretin Amyloidosis.
Am J Case Rep
December 2024
Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia.
BACKGROUND Amyloidosis is a group of diseases characterized by the pathological deposition of misfolded proteins in various organs, including the heart, leading to structural and functional alterations. The primary types of cardiac amyloidosis are light chain amyloidosis and transthyretin amyloidosis. Early diagnosis is critical for effective management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!